ArticleClinical and translational allergy2012
Research needs in allergy: an EAACI position paper, in collaboration with EFA.
Article in Clinical and translational allergy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 207 citations in OpenAlex.
- Birch Rust Spore Exposure and Upper Airway Symptom Dynamics in a Subarctic Region: Indications for a Novel Seasonal Allergen.Clinical and translational allergy · 2026Article
- Knowledge regarding respiratory allergy among primary care physicians in Georgia.Journal of family medicine and primary care · 2026Article
- Birch rust allergy as a novel autumnal trigger of seasonal airway symptoms.The journal of allergy and clinical immunology. Global · 2026Article
- Persistent Off-Season Dysregulation of Memory B Cell Subsets in Allergic Rhinitis.Clinical and translational allergy · 2025Article
- Severe drug-associated anaphylaxis: a complementary descriptive analyses of registry cases and spontaneous reports.European journal of clinical pharmacology · 2025Article
- Functional Assessment of Microplasma-Sprayed Hydroxyapatite-Zirconium Bilayer Coatings: Mechanical and Biological Perspectives.Materials (Basel, Switzerland) · 2025Article
- Exercise-Induced Angioedema, Urticaria, and Anaphylaxis-A Narrative Review.Sports (Basel, Switzerland) · 2025Review
- Article
- Allergy Inhibition Using Naturally Occurring Compounds Targeting Thymic Stromal Lymphopoietin Pathways: a Comprehensive Review.Biomolecules & therapeutics · 2025Review
- Asthma and stem cell therapy.World journal of stem cells · 2025Review
- From data to medical context: the power of categorization in healthcare.Frontiers in medicine · 2025Article
- Bacteria and Allergic Diseases.International journal of molecular sciences · 2024Review
- Optimization of Basophil Activation Test in the Diagnosis and Qualification for Allergen-Specific Immunotherapy in Children with Respiratory Allergy to the House Dust MiteInternational journal of molecular sciences · 2024Article
- Allergic and hypersensitivity condition in the International Patients' Summary (IPS) standard: The need of updates through the International Classification of Diseases (ICD)-11.The World Allergy Organization journal · 2024Review
- Structural and Immunological Features of PR-10 Allergens: Focusing on the Major Alder Pollen Allergen Aln g 1.International journal of molecular sciences · 2024Article
- Registries in allergy: Structure, target groups, and key findings of allergy-focused registries in Germany.Allergologie select · 2024Article
- A Catastrophic Biodiversity Loss in the Environment Is Being Replicated on the Skin Microbiome: Is This a Major Contributor to the Chronic Disease Epidemic?Microorganisms · 2023Article
- The Allergen Immunotherapy Adverse Events Registry: Setup & methodology of a European Academy of Allergy and Clinical Immunology taskforce project.Clinical and translational allergy · 2023Article
- Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China.Annals of medicine · 2022Article
- Associations between sensitisation to allergens and allergic diseases: a hospital-based case-control study in China.BMJ open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
136 authors at 20 institutions in 25 countries.
Funding
Abstract
In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21st century.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients' organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels.Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical syndromes into more coherent, uniform and treatment-responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient-oriented diagnostic and treatment protocols. Several allergic diseases require well-controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult-to-manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.